Wedbush Weighs in on Arvinas’ FY2029 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Research analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Arvinas in a research note issued on Tuesday, February 11th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.15) per share for the year. Wedbush has a “Outperform” rating and a $57.00 price target on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share.

ARVN has been the topic of several other reports. Stephens initiated coverage on Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a research report on Wednesday. Barclays cut their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Finally, BTIG Research started coverage on Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $60.00.

Arvinas Stock Performance

Arvinas stock opened at $18.31 on Thursday. The stock’s 50 day moving average price is $18.88 and its 200 day moving average price is $23.22. The firm has a market capitalization of $1.26 billion, a PE ratio of -3.92 and a beta of 1.88. Arvinas has a one year low of $16.61 and a one year high of $53.08.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. During the same period last year, the business earned ($2.53) EPS.

Institutional Investors Weigh In On Arvinas

A number of institutional investors have recently made changes to their positions in ARVN. nVerses Capital LLC bought a new stake in shares of Arvinas in the 3rd quarter valued at approximately $39,000. KBC Group NV grew its stake in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares during the last quarter. Quantbot Technologies LP grew its stake in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after buying an additional 2,601 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in Arvinas by 37.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after buying an additional 1,798 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.